Entero Healthcar

Has Entero Healthcar declared dividend?

No Dividend History Available

Who are the peers of the Entero Healthcar?

Entero Healthcare's peers include A B Lifestyle, Medplus Health, Aditya Vision, Khemani Distrib., M K Exim India, Purple United, Osia Hyper Retail, Purv Flexi, and Silgo Retail. Entero Healthcare shows average management risk and good growth, with a 1-year return of 4.75%, lower than Medplus Health's 38.34% but higher than Aditya Vision's -19.70%.

Peers: The peers of Entero Healthcar are A B Lifestyle, Medplus Health, Aditya Vision, Khemani Distrib., M K Exim India, Purple United, Osia Hyper Reta., Purv Flexi, and Silgo Retail.<BR><BR>Quality Snapshot: Excellent management risk is observed at Aditya Vision, Khemani Distrib., M K Exim India, and Purple United, while Average management risk is found at Entero Healthcar and the rest. Good growth is noted at Medplus Health, Aditya Vision, Khemani Distrib., M K Exim India, Purple United, and Osia Hyper Reta., while Entero Healthcar shows excellent growth and the rest have below average growth. For capital structure, excellent ratings are seen at Khemani Distrib. and M K Exim India, good at Entero Healthcar, and the rest have below average ratings.<BR><BR>Return Snapshot: Medplus Health has the highest 1-year return at 38.34%, while Aditya Vision has the lowest at -19.70%. Entero Healthcar's 1-year return is 4.75%, which is higher than Aditya Vision's but lower than Medplus Health's. Additionally, Khemani Distrib. is the only peer with a positive six-month return, while the rest have negative returns.

What does Entero Healthcar do?

Entero Healthcare Solutions Ltd is a mid-cap retail company, incorporated in 2018, with recent net sales of ₹13,391 Cr and a net profit of ₹257 Cr for the quarter ending March 2025. Key financial metrics include a P/E ratio of 55.00 and a market cap of ₹5,468 Cr.

Overview:<BR>Entero Healthcare Solutions Ltd operates in the retailing industry and is categorized as a mid-cap company.<BR><BR>History:<BR>The company was incorporated in 2018 as Entero Healthcare Solutions Private Limited and later converted into a public limited company, changing its name to Entero Healthcare Solutions Ltd. The latest quarterly results report net sales and net profit for the period ending March 2025.<BR><BR>Financial Snapshot:<BR>Most recent Net Sales: 13,391 Cr (Quarterly Results - Mar 2025) <BR>Most recent Net Profit: 257 Cr (Quarterly Results - Mar 2025) <BR>Market-cap value: INR 5,468 Cr (Mid Cap)<BR><BR>Key Metrics:<BR>P/E: 55.00 <BR>Industry P/E: 29 <BR>Dividend Yield: 0.00% <BR>Debt-Equity: 0.04 <BR>Return on Equity: 5.50% <BR>Price to Book: 3.15 <BR><BR>Contact Details:<BR>Registrar Address: Not available. <BR>Phone: N/A <BR>Email: N/A <BR>Website: N/A

Who are the top shareholders of the Entero Healthcar?

The top shareholders of Entero Healthcare include Orbimed Asia III Mauritius Limited with 38.01%, 70 foreign institutional investors holding 19.92%, and Surbhi Singh of the Prasid Uno Family Trust with 10.46%. Additionally, mutual funds hold 6.09%, while individual investors own 5.41% of the company.

The top shareholders of Entero Healthcare include several key players. The majority of the shares are held by promoters, with Orbimed Asia III Mauritius Limited being the largest individual promoter, holding 38.01%. Additionally, there are 70 foreign institutional investors (FIIs) collectively holding 19.92% of the shares. Mutual funds have a presence as well, with 7 schemes holding 6.09%. Among public shareholders, Surbhi Singh, representing the Prasid Uno Family Trust, is the largest, holding 10.46%. Individual investors collectively own 5.41% of the company.

How big is Entero Healthcar?

As of 24th July, Entero Healthcare Solutions Ltd has a market capitalization of 5,220.00 Cr, with net sales of 5,095.79 Cr and a net profit of 94.83 Cr reported for the latest four quarters. The company also has shareholder's funds of 1,638.06 Cr and total assets of 2,325.95 Cr for the annual period ending March 2024.

As of 24th July, Entero Healthcare Solutions Ltd has a market capitalization of 5,220.00 Cr, categorizing it as a Mid Cap company.<BR><BR>In the latest four quarters, Entero Healthcare reported net sales of 5,095.79 Cr and a net profit of 94.83 Cr.<BR><BR>For the latest annual period ending March 2024, the company reported shareholder's funds of 1,638.06 Cr and total assets of 2,325.95 Cr.

How has been the historical performance of Entero Healthcar?

Entero Healthcar has shown significant growth over the past five years, with net sales increasing from 1,779.74 Cr in March 2021 to 5,095.78 Cr in March 2025, and profit after tax turning positive at 107.43 Cr. The company has improved its operating profit and total assets while achieving a net cash inflow from investing activities in March 2025.

Answer:<BR>The historical performance of Entero Healthcar shows significant growth over the past five years, particularly in net sales and profitability.<BR><BR>Breakdown:<BR>Entero Healthcar's net sales have increased from 1,779.74 Cr in March 2021 to 5,095.78 Cr in March 2025, reflecting a strong upward trend. Total operating income has followed a similar trajectory, rising from 1,779.74 Cr to 5,095.78 Cr during the same period. The company's total expenditure, excluding depreciation, has also grown, reaching 4,924.23 Cr in March 2025, up from 1,758.19 Cr in March 2021. Operating profit, excluding other income, has improved significantly, moving from 21.55 Cr in March 2021 to 171.55 Cr in March 2025. This growth in operating profit has contributed to a profit before tax of 138.74 Cr in March 2025, a substantial increase from the losses recorded in previous years. The profit after tax has turned positive, reaching 107.43 Cr in March 2025, compared to losses in earlier years. The company's total assets have increased from 748.97 Cr in March 2020 to 2,688.21 Cr in March 2025, while total liabilities have also risen, from 748.97 Cr to 2,688.21 Cr. Cash flow from operating activities has shown negative trends, but cash flow from investing activities has turned positive in March 2025, indicating a net cash inflow of 81.00 Cr. Overall, Entero Healthcar has demonstrated a remarkable recovery and growth in its financial performance over the past five years.

Is Entero Healthcar overvalued or undervalued?

As of November 14, 2025, Entero Healthcare is considered very attractive and undervalued with a PE ratio of 44.13 and a PEG ratio of 0.31, despite a challenging year-to-date return of -20.6%, indicating strong growth potential compared to its peers.

As of 14 November 2025, Entero Healthcare has moved from an attractive to a very attractive valuation grade. The company is currently considered undervalued, with a PE ratio of 44.13, an EV to EBITDA of 23.43, and a PEG ratio of 0.31, indicating strong growth potential relative to its price. <BR><BR>In comparison to its peers, Entero's PE ratio significantly exceeds that of TCS at 22.34 and Infosys at 22.19, while its EV to EBITDA is higher than TCS's 15.7 but lower than that of LTI Mindtree at 23.98. Despite a challenging year with a year-to-date return of -20.6% compared to the Sensex's 8.22%, Entero Healthcare's strong valuation metrics suggest it remains an attractive investment opportunity in the retailing sector.

Is Entero Healthcar technically bullish or bearish?

As of November 19, 2025, Entero Healthcare's technical trend is bearish with moderate strength, indicated by bearish MACD, Bollinger Bands, moving averages, and KST, despite mixed signals from Dow Theory.

As of 19 November 2025, the technical trend has changed from mildly bearish to bearish. The current stance is bearish with moderate strength. Key indicators driving this include a bearish MACD on the weekly timeframe, bearish signals from Bollinger Bands on both weekly and monthly timeframes, and bearish moving averages on the daily timeframe. Additionally, the KST is bearish on the weekly, and the OBV shows a mildly bearish trend on the monthly. The Dow Theory reflects a mildly bullish stance on the weekly but is mildly bearish on the monthly, indicating mixed signals. Overall, the prevailing bearish indicators suggest a negative outlook for Entero Healthcare.

When is the next results date for Entero Healthcare Solutions Ltd?

The next results date for Entero Healthcare Solutions Ltd is 12 February 2026.

The next results date for Entero Healthcare Solutions Ltd is scheduled for 12 February 2026.

Are Entero Healthcare Solutions Ltd latest results good or bad?

Entero Healthcare Solutions Ltd's latest results show strong revenue growth with record net sales of ₹1,706.52 crores, but a 12.56% decline in net profit and decreasing profit margins raise concerns about profitability, suggesting a cautious outlook for investors.

Entero Healthcare Solutions Ltd's latest results present a mixed picture. On one hand, the company achieved record net sales of ₹1,706.52 crores in Q3 FY26, reflecting a strong 8.63% growth quarter-over-quarter (QoQ) and an impressive 25.57% growth year-over-year (YoY). This indicates robust demand for its pharmaceutical retail services and successful expansion efforts.<BR><BR>However, the consolidated net profit for the same quarter was ₹27.63 crores, which represents a concerning 12.56% decline QoQ, despite an 8.61% increase YoY. This decline raises questions about the company's ability to convert its revenue growth into sustainable profitability. Additionally, the profit after tax (PAT) margin decreased to 1.99%, down from 2.33% in the previous quarter, indicating pressure on profitability.<BR><BR>While the operating margin improved slightly to 3.97%, the overall financial performance suggests that Entero is facing operational challenges, particularly in managing costs and achieving consistent profit growth. The stock has also struggled recently, trading significantly below its 52-week high, which reflects market concerns about its financial stability and future profitability.<BR><BR>In summary, while Entero Healthcare's revenue growth is commendable, the decline in profit and margin pressures indicate that the results are more concerning than positive, warranting a cautious outlook from investors.

Should I buy, sell or hold Entero Healthcare Solutions Ltd?

Which are the latest news on Entero Healthcar?

Why is Entero Healthcare Solutions Ltd falling/rising?

As of 08-May, Entero Healthcare Solutions Ltd's stock price is declining at 1,224.80, down 3.11%, but strong financial performance and growth indicators suggest a favorable long-term outlook despite short-term market challenges.

As of 08-May, Entero Healthcare Solutions Ltd is experiencing a decline in its stock price, currently at 1,224.80, which reflects a change of -39.35 or -3.11%. This drop can be attributed to its performance today, where the stock underperformed its sector by 3.65%. Additionally, the stock touched an intraday low of Rs 1214.2, marking a decrease of 3.95%.<BR><BR>Despite this short-term decline, there are several positive factors that indicate a generally healthy long-term outlook for the company. Entero Healthcare has demonstrated strong financial performance, with net sales growing at an annual rate of 26.28% and operating profit increasing by 56.53%. The company has also reported positive results for the last eight consecutive quarters, with the highest quarterly profit after tax reaching Rs 34.49 crore and net sales hitting Rs 1,706.52 crore.<BR><BR>Moreover, the stock is trading above its moving averages, suggesting a potential for recovery, and there has been a notable increase in investor participation, with delivery volume rising by 27.67% against the five-day average. However, the current decline in stock price may be influenced by market sentiment and the stock's recent performance relative to the benchmark, as it has generated a return of -8.12% over the past year, despite profits rising by 32.7%. <BR><BR>In summary, while Entero Healthcare Solutions Ltd is currently facing a decline in stock price, its strong fundamentals and positive growth indicators suggest that the long-term outlook remains favorable.